Aurinia Pharmace Stock Price, News & Analysis

Aurinia Pharmaceuticals (NASDAQ: AUPH) has scheduled a conference call and webcast for June 30, 2025, at 8:30 a.m. ET to discuss the results of their Phase 1 study for AUR200. The company will provide dial-in options for both domestic (877-407-9170) and international (+1 201-493-6756) participants, with international toll-free access numbers available. A replay of the webcast will be made available on Aurinia's website following the presentation.

Aurinia Pharmaceuticals (NASDAQ: AUPH) presented new post-hoc analysis of its Phase 3 AURORA 1 study at LUPUS 2025, demonstrating superior efficacy of LUPKYNIS-based triple immunosuppressive therapy in lupus nephritis patients. The analysis showed that 60.9% of patients receiving LUPKYNIS with MMF and low-dose glucocorticoids achieved urine protein creatine ratio (UPCR) of ≤0.4 g/g, compared to 37.1% in the control group. Additional analysis revealed distinct lipidomic profiles in patients achieving ultra-low UPCR, suggesting potential cardiovascular benefits. The study found significant improvements in total and LDL cholesterol levels in the LUPKYNIS group. Importantly, adverse event rates remained comparable between treatment groups, supporting LUPKYNIS's safety profile. The findings emphasize LUPKYNIS's crucial role in achieving lower proteinuria targets and improving long-term kidney outcomes for lupus nephritis patients.

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported strong Q1 2025 financial results, with total revenue reaching $62.5 million, up 24% year-over-year. LUPKYNIS, their FDA-approved oral therapy for lupus nephritis, generated net product sales of $60.0 million, a 25% increase from 2024. The company achieved a significant turnaround with net income of $23.3 million, compared to a loss of $10.7 million in Q1 2024. Operating cash flow improved to $1.3 million, versus -$18.6 million last year. Aurinia maintained a strong cash position of $312.9 million and repurchased 5.8 million shares for $47.4 million. The company reaffirmed its 2025 guidance with total revenue of $250-260 million and net product sales of $240-250 million. Additionally, Aurinia expects to report initial results from its Phase 1 study of AUR200 later this quarter.

Aurinia Pharmaceuticals (NASDAQ: AUPH) has scheduled the release of its first quarter 2025 financial and operational results for May 12, 2025, before markets open. The company will host a conference call and webcast at 8:30 AM ET on the same day, where management will review the results and provide a business update. Investors can join via phone by dialing 877-407-9170 (domestic) or +1 201-493-6756 (international). A replay of the webcast will be available on Aurinia's website.

Aurinia Pharmaceuticals (NASDAQ: AUPH) has received a significant endorsement from Institutional Shareholder Services (ISS), a leading independent proxy advisor, for its upcoming 2025 Annual General Meeting scheduled for May 15, 2025.

ISS has recommended shareholders vote "FOR" all Board proposals, including:

• Approval of six director nominees
• Proposed auditor appointment
• Non-binding advisory vote on executive compensation
• Amendment to the Company's Equity Incentive Plan

Shareholders of record as of April 12, 2025, are eligible to vote. All votes must be submitted by 12:00 PM EST on May 13, 2025. Complete voting details and proposals are available in the proxy statement accessible through EDGAR and SEDAR+ platforms.

Concerned shareholders of Aurinia Pharmaceuticals (NASDAQ: AUPH) have announced their intention to withhold support for CEO Peter Greenleaf at the 2025 Annual Meeting. MKT Capital and Lucien Selce, significant stakeholders since 2019-2020, acknowledge positive changes under new Board Chair Kevin Tang, including:

• Board size reduction from 9 to 6 members
• Appointment of 4 new independent directors
• Discontinuation of non-core R&D programs saving $50M annually
• Launch of $150M share repurchase program
• Elimination of time-based RSUs for performance-based awards

Shareholders criticize Greenleaf's leadership, citing stock price depression at $8 (versus historical highs of $35), lack of transparency regarding patent infringement lawsuits against Hikma, Lotus, and Galenicum, and questionable compensation practices including 1.55M RSUs awarded despite underperformance. They demand Greenleaf's resignation and call for improved transparency, cost optimization, and receptiveness to M&A discussions.

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported strong financial results for Q4 and full-year 2024. Q4 total revenue reached $59.9M (up 33% YoY), with LUPKYNIS net product sales of $57.6M (up 36% YoY). The company achieved Q4 net income of $1.4M, compared to a loss of $26.9M in Q4 2023.

Full-year 2024 showed total revenue of $235.1M (up 34% YoY) and net product sales of $216.2M (up 36% YoY). The company reported annual net income of $5.8M, improving from a $78M loss in 2023. Cash position stood at $358.5M as of December 31, 2024.

For 2025 guidance, Aurinia expects total revenue of $250-260M and net product sales of $240-250M. The company also initiated a Phase 1 study of AUR200, a dual inhibitor for autoimmune diseases, with initial results expected in Q2 2025.

Aurinia Pharmaceuticals (NASDAQ: AUPH) has announced that it will release its 2024 fourth quarter and full year financial and operational results on February 27, 2025, before the market opens.

The company's management team will host a conference call and webcast at 8:30 am ET on the same day to review these results and provide a general business update. Interested parties can join the conference call by dialing 877-407-9170 (US) or +1 201-493-6756 (International).

A replay of the webcast will be available on Aurinia's website.

Aurinia Pharmaceuticals (NASDAQ: AUPH) welcomes the American College of Rheumatology's (ACR) 2024 guidelines for lupus nephritis (LN) treatment. The new guidelines recommend LUPKYNIS as first-line therapy in a triple immunosuppressive treatment regimen. Key highlights include steroid tapering to <5 mg/day by six months and achieving proteinuria target of <0.5g/g UPCR by 12 months. The AURORA 1 clinical study showed patients were 81% more likely to achieve complete renal response at 52 weeks with LUPKYNIS combination therapy versus standard treatment. Notably, >80% of patients reached steroid doses of <2.5mg/day by 16 weeks.